{"news_desk": "Business", "print_page": "1", "subsection_name": null, "section_name": "Business Day", "byline": {"original": "By KATIE THOMAS", "person": [{"firstname": "Katie", "rank": 1, "lastname": "THOMAS", "organization": "", "role": "reported"}]}, "abstract": "Country's largest patient advocacy groups have mostly avoided public debate over skyrocketing drug prices; many of these groups, which are hugely influence on Capitol Hill, get millions of dollars annually in donations from drug firms; critics say groups, by avoiding cost debate, are shirking patient-advocacy responsibilities. ", "type_of_material": "News", "word_count": "1423", "keywords": [{"rank": "1", "value": "Drugs (Pharmaceuticals)", "is_major": "Y", "name": "subject"}, {"rank": "11", "value": "Lobbying and Lobbyists", "is_major": "N", "name": "subject"}, {"rank": "2", "value": "Health Insurance and Managed Care", "is_major": "Y", "name": "subject"}, {"rank": "3", "value": "Conflicts of Interest", "is_major": "N", "name": "subject"}, {"rank": "4", "value": "Prices (Fares, Fees and Rates)", "is_major": "N", "name": "subject"}, {"rank": "5", "value": "National Health Council", "is_major": "N", "name": "organizations"}, {"rank": "6", "value": "American Diabetes Assn", "is_major": "N", "name": "organizations"}, {"rank": "7", "value": "Leukemia & Lymphoma Society", "is_major": "N", "name": "organizations"}, {"rank": "8", "value": "Mylan Inc", "is_major": "N", "name": "organizations"}, {"rank": "9", "value": "National Multiple Sclerosis Society", "is_major": "N", "name": "organizations"}, {"rank": "10", "value": "Pharmaceutical Research and Manufacturers of America", "is_major": "N", "name": "organizations"}], "lead_paragraph": "Many groups ostensibly on the side of patients find themselves conflicted by the millions they receive from the pharmaceutical industry.", "pub_date": "2016-09-28T04:00:00+0000", "document_type": "article", "source": "The New York Times", "snippet": "Many groups ostensibly on the side of patients find themselves conflicted by the millions they receive from the pharmaceutical industry....", "multimedia": [{"height": 126, "subtype": "wide", "legacy": {"widewidth": "190", "wide": "images/2016/09/28/business/28PATIENTS/28PATIENTS-thumbWide.jpg", "wideheight": "126"}, "type": "image", "width": 190, "url": "images/2016/09/28/business/28PATIENTS/28PATIENTS-thumbWide.jpg"}, {"height": 400, "subtype": "xlarge", "legacy": {"xlargewidth": "600", "xlargeheight": "400", "xlarge": "images/2016/09/28/business/28PATIENTS/28PATIENTS-articleLarge.jpg"}, "type": "image", "width": 600, "url": "images/2016/09/28/business/28PATIENTS/28PATIENTS-articleLarge.jpg"}, {"height": 75, "subtype": "thumbnail", "legacy": {"thumbnailwidth": "75", "thumbnail": "images/2016/09/28/business/28PATIENTS/28PATIENTS-thumbStandard.jpg", "thumbnailheight": "75"}, "type": "image", "width": 75, "url": "images/2016/09/28/business/28PATIENTS/28PATIENTS-thumbStandard.jpg"}], "web_url": "http://www.nytimes.com/2016/09/28/business/furor-over-drug-prices-puts-patient-advocacy-groups-in-bind.html", "slideshow_credits": null, "blog": [], "_id": "57eb087a95d0e021d7988b70", "headline": {"main": "Furor Over Drug Prices Puts Patient Advocacy Groups in Bind", "print_headline": "Loyalties Split, Patient Groups Skip Drug Price Debate"}}